Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy

Circulation

Volumn 102, Issue 17, 2000, Pages 2051-2057

  Holmes, Michael B ^a   Schneider, David J ^a   Hayes, Michael G ^a   Sobel, Burton E ^a   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulants; Coagulation; Platelets

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT THROMBOPLASTIN; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; TRYPSIN INHIBITOR;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL TRIAL; DRUG EFFICACY; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOSIS;

EID: 0034711142     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.17.2051     Document Type: Article

References (25)

1. Tissue factor and hemostasis
2. Blood clotting in minimally altered whole blood
3. Platelet procoagulant complex assembly in a tissue factor-initiated system
4. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Future directions
5. Activated coagulation time of whole blood
6. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy
7. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
8. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
9. The influence of heparin on the prothrombin time
10. A model for the tissue factor pathway to thrombin, I: An empirical study
11. A model for the tissue factor pathway to thrombin, II: A mathematical simulation
12. Extrinsic pathway proteolytic activity
13. Blood coagulation in hemophilia A and hemophilia C
14. The effect of thrombocytopenia on the tissue factor pathway
15. Direct thrombin inhibitor in cardiovascular disease
16. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
17. Clinical evaluation of rNAPc2, an inhibitor of the fVIIa/tissue factor coagulation complex
18. Anticoagulant repertoire of the hookworm Ancylostoma caninum
19. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
20. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: A randomized multicenter trial
21. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
22. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: A randomized trial
23. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time
24. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
25. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous revascularization